By Colin Kellaher
Zevra Therapeutics has inked a deal to sell its Food and Drug Administration priority-review voucher to an undisclosed buyer for gross proceeds of $150 million.
Zevra, which won the voucher upon FDA approval of its Miplyffa drug for the rare neurodegenerative disorder Niemann-Pick disease type C, on Thursday said it expects to complete the sale within 30 to 45 days.
The FDA awards the vouchers upon approval of drugs previously granted rare-pediatric-disease designation, and they can be used to obtain priority review for another drug or sold to other companies. Acadia Pharmaceuticals and PTC Therapeutics last year struck deals to sell vouchers for $150 million apiece.
Zevra, a Celebration, Fla., rare-disease company, said it will use the sale proceeds to support the commercial launches of its Miplyffa and Olpruva drugs and to advance its pipeline of product candidates.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 27, 2025 10:14 ET (15:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.